BAT1406 is an adalimumab biosimilar that has been systematically compared to the original drug during the R&D processes, including a pharmacodynamic evaluation in acute and chronic inflammation animal models. Through specific binding to TNF-α and the neutralization effect, BAT1406 blocks interaction of TNF-α with cell surface TNF receptors p55 and p75 and thus inhibits its inflammatory effect.

Adalimumab was the world's first approved fully human anti-TNF-α monoclonal antibody and has been approved for eight different indications including rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and uveitis.